Cardinal buys up Alaris shares:
This article was originally published in Clinica
Executive Summary
Cardinal Health has completed its tender offer for all outstanding shares of common stock of Alaris Medical Systems. As previously announced, Cardinal purchased the shares at a price of $22.35 each in cash as part of its plan to acquire San Diego, California-based Alaris. The final steps to completing the merger - in which the developer of needle-free valves and systems will become a wholly-owned Cardinal subsidiary - is going ahead despite the dark cloud of litigation hanging over Alaris. At the end of last month, ICU Medical had filed a patent lawsuit against San Diego, California-based Alaris concerning the latter's SmartSite and SmartSite Plus needle-free valves and systems (see Clinica No 1113, p 12).
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.